Antivascular cancer treatments: Functional assessments by dynamic contrast-enhanced magnetic resonance imaging

Abdominal Imaging

Volumn 30, Issue 3, 2005, Pages 324-341

  Padhani, A R ^a   Leach, M O ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antiangiogenesis drugs; Clinical trials phase 1; Magnetic resonance imaging; Tumor perfusion; Tumor permeability

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CONTRAST MEDIUM; GADOLINIUM PENTETATE; GEFITINIB; IMATINIB; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

CANCER; CANCER INVASION; CANCER RESEARCH; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MICROVASCULATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 21244434377     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-004-0265-5     Document Type: Review

References (146)

1. EM Conway D Collen P Carmeliet 2001 Molecular mechanisms of blood vessel growth Cardiovasc Res. 49 507 521
2. J Folkman 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med. 1 27 31
3. K Kaban RS Herbst 2002 Angiogenesis as a target for cancer therapy Hematol Oncol Clin North Am. 16 1125 1171
4. PL Choyke AJ Dwyer MV Knopp 2003 Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging J Magn Reson Imaging 17 509 520
5. GJ Parker PS Tofts 1999 Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging Top Magn Reson Imaging 10 130 142
6. AR Padhani 2002 Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions J Magn Reson Imaging 16 407 422
7. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 11th scientific meeting. Toronto, 2003:1268.
8. J Folkman 1996 New perspectives in clinical oncology from angiogenesis research Eur J Cancer 32A 2534 2539
9. JW Rak BD St Croix RS Kerbel 1995 Consequences of angiogenesis for tumor progression, metastasis and cancer therapy Anticancer Drugs 6 3 18
10. R Gilles B Zafrani JM Guinebretiere 1995 Ductal carcinoma in situ: MR imaging-histopathologic correlation Radiology 196 415 419
11. YN Park YB Kim KM Yang C Park 2000 Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis Arch Pathol Lab Med 124 1061 1065
12. G Gasparini M Toi R Miceli 1999 Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Cancer J Sci Am 5 101 111
13. A Obermair E Kucera K Mayerhofer 1997 Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival Int J Cancer 74 455 458
14. B Linderholm B Tavelin K Grankvist R Henriksson 1998 Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma J Clin Oncol. 16 3121 3128
15. N Weidner 1998 Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow J Pathol. 184 119 122
16. M Neeman JM Provenzale MW Dewhirst 2001 Magnetic resonance imaging applications in the evaluation of tumor angiogenesis Semin Radiat Oncol. 11 70 82
17. HF Dvorak JA Nagy D Feng 1999 Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis Curr Top Microbiol Immunol 237 97 132
18. LE Benjamin D Golijanin A Itin 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165
19. MW Dewhirst 1993 Angiogenesis and blood flow in solid tumors B Teicher Drug resistance in oncology Marcel Dekker New York 3 24
20. RD Braun JL Lanzen MW Dewhirst 1999 Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats Am J Physiol. 277 H551 568
21. PB Vermeulen G Gasparini SB Fox 1996 Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation Eur J Cancer 32A 2474 2484
22. OA Kerckhaert EE Voest 2001 The prognostic and diagnostic value of circulating angiogenic factors in cancer patients EE Voest PA D'Amore Tumor angiogenesis and microcirculation Marcel Dekker New York 487 500
23. B Endrich P Vaupel 1998 The role of microcirculation in the treatment of malignant tumors: facts and fiction M Molls P Vaupel Blood perfusion and microenvironment of human tumors Springer-Verlag Berlin 19 39
24. ZM Bhujwalla D Artemov J Glockner 1999 Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imaging Top Magn Reson Imaging 10 92 103
25. RJ Gillies ZM Bhujwalla J Evelhoch 2000 Applications of magnetic resonance in model systems: tumor biology and physiology Neoplasia 2 139 151
26. R Brasch K Turetschek 2000 MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report Eur J Radiol. 34 148 155
27. RC Brasch KC Li JE Husband 2000 In vivo monitoring of tumor angiogenesis with MR imaging Acad Radiol. 7 812 823
28. R Weissleder U Mahmood 2001 Molecular imaging Radiology 219 316 333
29. FA Howe SP Robinson DJ McIntyre 2001 Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours NMR Biomed. 14 497 506
30. HE Daldrup DM Shames W Husseini 1998 Quantification of the extraction fraction for gadopentetate across breast cancer capillaries Magn Reson Med 40 537 543
31. PS Tofts G Brix DL Buckley 1999 Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 223 232
32. EL Barbier L Lamalle M Decorps 2001 Methodology of brain perfusion imaging J Magn Reson Imaging 13 496 520
33. AG Sorensen AL Tievsky L Ostergaard 1997 Contrast agents in functional MR imaging J Magn Reson Imaging 7 47 55
34. CZ Simonsen L Ostergaard DF Smith 2000 Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking J Magn Reson Imaging 12 411 416
35. J Dennie JB Mandeville JL Boxerman 1998 NMR imaging of changes in vascular morphology due to tumor angiogenesis Magn Reson Med. 40 793 799
36. R Bruening C Berchtenbreiter N Holzknecht 2000 Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader study AJNR 21 1603 1610
37. BR Rosen JW Belliveau BR Buchbinder 1991 Contrast agents and cerebral hemodynamics Magn Reson Med. 19 285 292
38. F Wenz K Rempp T Hess 1996 Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging AJR 166 187 193
39. ME Moseley Z Vexler HS Asgari 1991 Comparison of Gd- and Dy-chelates for T2 contrast-enhanced imaging Magn Reson Med. 22 259 264
40. P Reimer G Schuierer T Balzer PE Peters 1995 Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume Magn Reson Med. 34 694 697
41. JA d'Arcy DJ Collins IJ Rowland 2002 Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI NMR Biomed. 15 174 183
42. EA Knopp S Cha G Johnson 1999 Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging Radiology 211 791 798
43. T Ichikawa H Haradome J Hachiya 1998 Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence AJR 170 1029 1034
44. T Ichikawa AS Arbab T Araki 1999 Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma AJR 173 207 213
45. CK Kuhl H Bieling J Gieseke 1997 Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging Radiology 202 87 95
46. KA Kvistad S Lundgren HE Fjosne 1999 Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging Acta Radiol 40 45 51
47. KL Weind CF Maier BK Rutt M Moussa 1998 Invasive carcinomas and fibroadenomas of the breast: comparison of microvessel distributions- implications for imaging modalities Radiology 208 477 483
48. Yung WKA, Friedman H, Conrad C, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. In: American Society of Clinical Oncology. Chicago, 2003:395
49. HB Larsson M Stubgaard JL Frederiksen 1990 Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors Magn Reson Med. 16 117 131
50. P Gowland P Mansfield P Bullock 1992 Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echo-planar imaging Magn Reson Med. 26 241 258
51. GJ Parker J Suckling SF Tanner 1997 Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics J Magn Reson Imaging 7 564 574
52. FW Flickinger JD Allison RM Sherry JC Wright 1993 Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI Magn Reson Imaging 11 617 620
53. WA Kaiser E Zeitler 1989 MR imaging of the breast: fast imaging sequences with and without Gd-DTPA Preliminary observations Radiology 170 681 686
54. IS Gribbestad G Nilsen HE Fjosne 1994 Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography J Magn Reson Imaging 4 477 480
55. JL Evelhoch 1999 Key factors in the acquisition of contrast kinetic data for oncology J Magn Reson Imaging 10 254 259
56. GJ Parker I Baustert SF Tanner MO Leach 2000 Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter Magn Reson Imaging 18 157 167
57. PS Tofts 1997 Modeling tracer kinetics in dynamic Gd-DTPA MR imaging J Magn Reson Imaging 7 91 101
58. PS Tofts B Berkowitz MD Schnall 1995 Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model Magn Reson Med. 33 564 568
59. CS Landis X Li FW Telang 2000 Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange Magn Reson Med. 44 563 574
60. DL Buckley 2002 Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo Magn Reson Med. 47 420 421
61. HJ Weinmann M Laniado W Mutzel 1984 Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers Physiol Chem Phys Med NMR 16 167 172
62. M Rijpkema JH Kaanders FB Joosten 2001 Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors J Magn Reson Imaging 14 457 463
63. DL Buckley 2002 Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T(1)-weighted MRI Magn Reson Med. 47 601 606
64. PC Stomper JS Winston S Herman 1997 Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions Breast Cancer Res Treat 45 39 46
65. H Hawighorst PG Knapstein W Weikel 1997 Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement Cancer Res. 57 4777 4786
66. O Tynninen HJ Aronen M Ruhala 1999 MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation Invest Radiol. 34 427 434
67. DL Buckley PJ Drew S Mussurakis 1997 Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI J Magn Reson Imaging 7 461 464
68. CA Hulka WB Edmister BL Smith 1997 Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis Radiology 205 837 842
69. RA Cooper BM Carrington JA Loncaster 2000 Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix Radiother Oncol. 57 53 59
70. MY Su YC Cheung JP Fruehauf 2003 Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer J Magn Reson Imaging 18 467 477
71. MV Knopp E Weiss HP Sinn 1999 Pathophysiologic basis of contrast enhancement in breast tumors J Magn Reson Imaging 10 260 266
72. ZM Bhujwalla D Artemov K Natarajan 2001 Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts Neoplasia 3 143 153
73. CD Pham TP Roberts N van Bruggen 1998 Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor Cancer Invest 16 225 230
74. A Gossmann TH Helbich N Kuriyama 2002 Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme J Magn Reson Imaging 15 233 240
75. Thomas A, Morgan B, Drevs J, et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. In: Proceedings of American Society of Clinical Oncology. San Francisco, 2001:A279
76. R Matsubayashi Y Matsuo G Edakuni 2000 Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors Radiology 217 841 848
77. Y Yamashita T Baba Y Baba 2000 Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy Radiology 216 803 809
78. H Lyng AO Vorren K Sundfor 2001 Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging J Magn Reson Imaging 14 750 756
79. H Konouchi J Asaumi Y Yanagi 2003 Evaluation of tumor proliferation using dynamic contrast enhanced-MRI of oral cavity and oropharyngeal squamous cell carcinoma Oral Oncol. 39 290 295
80. HJ van der Woude KL Verstraete PC Hogendoorn 1998 Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 208 821 828
81. PF Liu GP Krestin RA Huch 1998 MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging Eur Radiol. 8 1433 1440
82. JO Barentsz GJ Jager PB van Vierzen 1996 Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging Radiology 201 185 193
83. GJ Jager ET Ruijter CA van de Kaa 1997 Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results Radiology 203 645 652
84. RA Huch Boni JA Boner UM Lutolf 1995 Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma J Comput Assist Tomogr 19 232 237
85. H Hawighorst W Weikel PG Knapstein 1998 Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome Clin Cancer Res 4 2305 2312
86. NA Mayr WT Yuh VA Magnotta 1996 Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay Int J Radiat Oncol Biol Phys. 36 623 633
87. R Gilles JM Guinebretiere LG Shapeero 1993 Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients Radiology 188 473 478
88. RW Kerslake JN Fox PJ Carleton 1994 Dynamic contrast-enhanced and fat suppressed magnetic resonance imaging in suspected recurrent carcinoma of the breast: preliminary experience Br J Radiol. 67 1158 1168
89. S Mussurakis DL Buckley SJ Bowsley 1995 Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma Invest Radiol. 30 650 662
90. K Kinkel AA Tardivon P Soyer 1996 Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients Radiology 200 453 458
91. JM Hawnaur XP Zhu CE Hutchinson 1998 Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer Br J Radiol. 71 1136 1142
92. TH Dao A Rahmouni F Campana 1993 Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging Radiology 187 751 755
93. SH Heywang-Kobrunner A Schlegel R Beck 1993 Contrast-enhanced MRI of the breast after limited surgery and radiation therapy J Comput Assist Tomogr 17 891 900
94. L Blomqvist P Fransson T Hindmarsh 1998 The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging Eur Radiol 8 781 787
95. JO Barentsz O Berger-Hartog JA Witjes 1998 Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging Radiology 207 791 797
96. WE Reddick JS Taylor BD Fletcher 1999 Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma J Magn Reson Imaging 10 277 285
97. HJ van der Woude JL Bloem KL Verstraete 1995 Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery AJR 165 593 598
98. MV Knopp G Brix HJ Junkermann HP Sinn 1994 MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy Magn Reson Imaging Clin North Am 2 633 658
99. Padhani AR, Hayes C, Assersohn L, et al. Response of breast carcinoma to chemotherapy-MR permeability changes using histogram analysis. In: International Society for Magnetic Resonance in Medicine, 8th scientific meeting. Denver, 2000:2160
100. AF Devries J Griebel C Kremser 2001 Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma Cancer Res. 61 2513 2516
101. A de Vries J Griebel C Kremser 2000 Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy Radiology 217 385 391
102. NA Mayr WT Yuh JC Arnholt 2000 Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer J Magn Reson Imaging 12 1027 1033
103. ML George AS Dzik-Jurasz AR Padhani 2001 Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer Br J Surg. 88 1628 1636
104. AR Padhani AD MacVicar CJ Gapinski 2001 Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging Radiology 218 365 374
105. PR Burn JM McCall RJ Chinn 2000 Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteries Radiology 214 729 734
106. RC Jha SM Ascher I Imaoka JB Spies 2000 Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization Radiology 217 228 235
107. W Li DP Brophy Q Chen 2000 Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization J Magn Reson Imaging 12 1004 1008
108. Lankester KJ, Taylor NJ, Stirling JJ, et al. Conventional cytotoxic chemotherapy agents do not have acute antivascular effects, as measured by dynamic contrast enhanced MRI (DCE-MRI). In: Proceedings of the American Society of Clinical Oncology, 39th annual meeting. Chicago, 2003:588
109. SM Galbraith RJ Maxwell MA Lodge 2003 Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol. 21 2831 2842
110. Ah-See MW, Taylor NJ, Makris A, et al. Preliminary evaluation of multi-functional MRI to predict response to neoadjuvant chemotherapy in primary breast cancer. In: Proceedings of the American Society of Clinical Oncology, 39th annual meeting. Chicago, 2003:556
111. P Workman 2002 Challenges of PK/PD measurements in modern drug development Eur J Cancer 38 2189 2193
112. JK Buolamwini 1999 Novel anticancer drug discovery Curr Opin Chem Biol. 3 500 509
113. B Morgan AL Thomas J Drevs 2003 Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol. 21 3955 3964
114. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med. 349 427 434
115. P Vajkoczy MD Menger B Vollmar 1999 Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy Neoplasia 1 31 41
116. J Drevs R Muller-Driver C Wittig 2002 PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging Cancer Res. 62 4015 4022
117. GC Jayson J Zweit A Jackson 2002 Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies J Natl Cancer Inst. 94 1484 1493
118. SM Galbraith GJ Rustin MA Lodge 2002 Effects of 5,6-dimethylxanthenone-4- acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging J Clin Oncol. 20 3826 3840
119. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. In: American Society of Clinical Oncology. Chicago, 2003:3646
120. SM Galbraith RJ Maxwell MA Lodge 2003 Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging J Clin Oncol. 21 2831 2842
121. SM Galbraith DJ Chaplin F Lee 2001 Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo Anticancer Res. 21 93 102
122. RJ Maxwell J Wilson VE Prise 2002 Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI NMR Biomed. 15 89 98
123. K Turetschek A Preda E Floyd 2003 MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model Eur J Nucl Med Mol Imaging 30 448 455
124. D Checkley JJ Tessier J Kendrew 2003 Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours Br J Cancer 89 1889 1895
125. O'Donell A, Trigo J, Raynaud F, et al. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast enhanced MRI assessment of vascular permeability. In: 36th Annual meeting of the American Society of Clinical Oncology. New Orleans, 2000:685
126. U Hoffmann G Brix MV Knopp 1995 Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography Magn Reson Med. 33 506 514
127. JA den Boer RK Hoenderop J Smink 1997 Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions J Magn Reson Imaging 7 702 715
128. H Degani V Gusis D Weinstein 1997 Mapping pathophysiological features of breast tumors by MRI at high spatial resolution Nat Med. 3 780 782
129. Evelhoch J, Brown T, Chenevert T, et al. Consensus recommendation for acquisition of dynamic contrast-enhanced MRI data in oncology. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Denver, 2000:1439
130. J Brown D Buckley A Coulthard 2000 Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group Magn Reson Imaging 18 765 776
131. PS Tofts AG Kermode 1991 Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts Magn Reson Med 17 357 367
132. G Brix W Semmler R Port 1991 Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging J Comput Assist Tomogr 15 621 628
133. E Henderson BK Rutt TY Lee 1998 Temporal sampling requirements for the tracer kinetics modeling of breast disease Magn Reson Imaging 16 1057 1073
134. PS Tofts BA Berkowitz 1994 Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods Magn Reson Imaging 12 81 91
135. RE Port MV Knopp U Hoffmann 1999 Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging J Magn Reson Imaging 10 233 241
136. L Ludemann B Hamm C Zimmer 2000 Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging Magn Reson Imaging 18 1201 1214
137. TP Roberts 1997 Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations J Magn Reson Imaging 7 82 90
138. Taylor NJ, Lankester KJ, Stirling JJ, et al. Application of navigator techniques to breath-hold DCE-MRI studies of the liver. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 11th scientific meeting. Toronto, 2003:1306
139. Noseworthy MD, Sussman MS, Haider M, Baruchel S. Dynamic contrast enhanced liver MRI using a motion tracking algorithm. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Glasgow, Scotland, 2001:2240
140. JM Bland DG Altman 1996 Measurement error (a) BMJ 313 744
141. A Jackson A Kassner XP Zhu KL Li 2001 Reproducibility of T2*blood volume and vascular tortuosity maps in cerebral gliomas J Magn Reson Imaging 14 510 516
142. SM Galbraith MA Lodge NJ Taylor 2002 Reproducibility of dynamic contrast enhanced MRI in human muscle and tumours-comparison of quantitative and semi-quantitative analysis NMR Biomed. 15 132 142
143. AR Padhani C Hayes S Landau MO Leach 2002 Reproducibility of quantitative dynamic MRI of normal human tissues NMR Biomed. 15 143 154
144. Evelhoch J, LoRusso P, Latif Z, et al. Reproducibility of dynamic contrast-enhanced (DCE-MRI) assessment of tumor vascularity. In: American Society of Clinical Oncology 2001 annual meeting. San Francisco, 2001:399
145. HJ Aronen IE Gazit DN Louis 1994 Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings Radiology 191 41 51
146. C Hayes AR Padhani MO Leach 2002 Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging NMR Biomed. 15 154 163